Stock Analysis

3 US Penny Stocks With Market Caps Over $30M To Watch

After two days of record highs, the U.S. stock market saw a decline with major indices like the Dow Jones and Nasdaq posting losses. In such fluctuating conditions, investors often look for opportunities in various segments of the market, including penny stocks. Although considered an outdated term, penny stocks still represent smaller or newer companies that can offer both affordability and growth potential when backed by strong financials.

Advertisement

Top 10 Penny Stocks In The United States

NameShare PriceMarket CapFinancial Health Rating
QuantaSing Group (NasdaqGM:QSG)$3.08$132.89M★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)$2.78$85.54M★★★★★★
Permianville Royalty Trust (NYSE:PVL)$1.44$47.85M★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)$4.50$67.38M★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)$0.2695$9.57M★★★★★★
PHX Minerals (NYSE:PHX)$4.20$156.67M★★★★★☆
Smith Micro Software (NasdaqCM:SMSI)$1.43$24.83M★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)$0.8696$79.96M★★★★★☆
BAB (OTCPK:BABB)$0.83$6.31M★★★★★☆
Lifetime Brands (NasdaqGS:LCUT)$4.95$110.78M★★★★★☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Aadi Bioscience (NasdaqCM:AADI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers involving mTOR pathway gene alterations, with a market cap of $70.74 million.

Operations: The company generates revenue of $25.07 million from its segment focused on the development and commercialization of proprietary therapeutics.

Market Cap: $70.74M

Aadi Bioscience, Inc., with a market cap of US$70.74 million, is navigating significant strategic shifts amid its unprofitable status and volatile share price. The recent appointment of Dr. David Dornan as Chief Scientific Officer underscores the company's focus on advancing its portfolio of antibody-drug conjugates (ADCs). Aadi's strategic plan includes selling FYARRO® for US$100 million and acquiring ADC assets from WuXi Biologics, supported by a US$100 million private placement financing. Despite financial challenges, Aadi remains debt-free with sufficient short-term assets to cover liabilities and an experienced board guiding these transformative efforts.

NasdaqCM:AADI Debt to Equity History and Analysis as at Feb 2025
NasdaqCM:AADI Debt to Equity History and Analysis as at Feb 2025

PodcastOne (NasdaqCM:PODC)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PodcastOne, Inc. operates as a podcast platform and publisher with a market cap of $50.54 million.

Operations: The company generates $49.73 million in revenue from its Internet Information Providers segment.

Market Cap: $50.54M

PodcastOne, Inc., with a market cap of US$50.54 million, is navigating the competitive podcasting landscape amid its unprofitable status. Recent developments include a renewed partnership with Kailyn Lowry and an agreement with ART19 LLC for enhanced monetization opportunities, ensuring a minimum guarantee of US$15 million over three years. The company reported third-quarter sales of US$12.71 million and reduced net losses compared to the previous year. Despite high share price volatility and limited cash runway, PodcastOne's revenue is projected to grow by 17% annually as it seeks acquisitions to bolster growth prospects in this dynamic sector.

NasdaqCM:PODC Debt to Equity History and Analysis as at Feb 2025
NasdaqCM:PODC Debt to Equity History and Analysis as at Feb 2025

Investview (OTCPK:INVU)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Investview, Inc., through its subsidiaries, offers financial products and services focused on financial education, digital assets, and related technology for individuals, with a market cap of $38.21 million.

Operations: The company generates revenue of $58.45 million from its online financial information provider segment.

Market Cap: $38.21M

Investview, Inc., with a market cap of US$38.21 million, has recently become profitable, marking a significant turnaround from its previous financial struggles. The company's short-term assets of US$30.8 million exceed both its short and long-term liabilities, indicating strong liquidity. Despite this progress, the company faced a regulatory challenge with the SEC concerning past unregistered investment contracts related to bitcoin mining equipment sales, resulting in a US$375,000 penalty settlement. While INVU's debt is well-covered by operating cash flow and interest payments are manageable at 4.5 times coverage by EBIT, share price volatility remains high at 25%.

OTCPK:INVU Debt to Equity History and Analysis as at Feb 2025
OTCPK:INVU Debt to Equity History and Analysis as at Feb 2025

Summing It All Up

  • Navigate through the entire inventory of 712 US Penny Stocks here.
  • Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
  • Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Whitehawk Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqCM:WHWK

Whitehawk Therapeutics

An oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.

Flawless balance sheet with slight risk.

Advertisement

Updated Narratives

BL
BlackGoat
GOOG logo
BlackGoat on Alphabet ·

Alphabet: The Under-appreciated Compounder Hiding in Plain Sight

Fair Value:US$324.481.3% undervalued
74 users have followed this narrative
3 users have commented on this narrative
1 users have liked this narrative
BE
Bejgal
MNSO logo
Bejgal on MINISO Group Holding ·

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fair Value:US$26.6926.7% undervalued
45 users have followed this narrative
3 users have commented on this narrative
0 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8147.4% undervalued
9 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
GOOGL logo
oscargarcia on Alphabet ·

The company that turned a verb into a global necessity and basically runs the modern internet, digital ads, smartphones, maps, and AI.

Fair Value:US$3405.9% undervalued
136 users have followed this narrative
6 users have commented on this narrative
18 users have liked this narrative
TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
89 users have followed this narrative
10 users have commented on this narrative
18 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$232.7922.6% undervalued
927 users have followed this narrative
6 users have commented on this narrative
22 users have liked this narrative